ITRM — Iterum Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $38.04m
- $59.45m
Annual income statement for Iterum Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 34.6 | 24.5 | 47.7 | 47.5 | 18.7 |
| Operating Profit | -34.6 | -24.5 | -47.7 | -47.5 | -18.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -51.3 | -90.9 | -44.1 | -37.8 | -24.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -52 | -91.6 | -44.4 | -38.4 | -24.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -52 | -91.6 | -44.4 | -38.4 | -24.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -52 | -91.6 | -44.4 | -38.4 | -24.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -31.5 | -8.41 | -2.71 | -2.96 | -1.26 |